Download PDF
Horm Metab Res 2011; 43(12): 890-896
DOI: 10.1055/s-0031-1284382
Review
© George Thieme Verlag KG Stuttgart · New York

The Immune System in Neuroendocrine Tumors

A. Thiel
1   University Hospital Düsseldorf, Department of Endocrinology, Diabetology and Rheumatology, Düsseldorf, Germany
,
M. Ehlers
1   University Hospital Düsseldorf, Department of Endocrinology, Diabetology and Rheumatology, Düsseldorf, Germany
,
M. Anlauf
2   University Hospital Düsseldorf, Institute of Pathology and Endocrine Tumor Center, Düsseldorf, Germany
,
A. Raffel
3   University Hospital Düsseldorf, Department of General, Visceral and Pediatric Surgery, Düsseldorf, Germany
,
N. H. Stoecklein
3   University Hospital Düsseldorf, Department of General, Visceral and Pediatric Surgery, Düsseldorf, Germany
,
M. Schott
1   University Hospital Düsseldorf, Department of Endocrinology, Diabetology and Rheumatology, Düsseldorf, Germany
› Author Affiliations
Further Information

Publication History

received23 May 2011

accepted 08 July 2011

Publication Date:
04 October 2011 (online)

Also available at
    Permissions and Reprints

Abstract

During the last 30 years the incidence of neuroendocrine tumors has increased considerably and the overall 5-year survival rate has not changed substantially. Conventional therapeutic approaches appear to show an unsatisfactory effect in the more insidious forms of malignancies. Hence, attempts were made to direct the patient’s own immune system against cancer by vaccinating against different tumor antigens. Up to date, only sporadic achievements were demonstrated in the majority cases of vaccination trials. One of the main hindrances to a successful vaccination comprises tumor-immune-escape mechanisms. This review focuses on the current knowledge concerning tumor immunoevasion strategies and the immune system in neuroendocrine tumors.

Key words

neuroendocrine malignancies - NET - tumor-immune-escape - immunoevasion
 

  • References

  • 1 Volante M, Righi L, Berruti A, Rindi G, Papotti M. The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers. Virchows Arch 2011; 458: 393-402
    CrossrefPubMedGoogle Scholar
  • 2 Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle FG, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9: 61-72
    CrossrefPubMedGoogle Scholar
  • 3 Righi L, Volante M, Rapa I, Scagliotti GV, Papotti M. Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data. Virchows Arch 2007; 451 (Suppl 1) S51-S59
    CrossrefPubMedGoogle Scholar
  • 4 Georgantzi K, Tsolakis AV, Stridsberg M, Jakobson A, Christofferson R, Janson ET. Differentiated expression of somatostatin receptor subtypes in experimental models and clinical neuroblastoma. Pediatr Blood Cancer 2011; 56: 584-589
    CrossrefPubMedGoogle Scholar
  • 5 Navalkele P, O’Dorisio MS, O’Dorisio TM, Zamba GK, Lynch CF. Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975–2006. Pediatr Blood Cancer 2011; 56: 50-57
    CrossrefPubMedGoogle Scholar
  • 6 Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr Relat Cancer 2004; 11: 1-18
    CrossrefPubMedGoogle Scholar
  • 7 Farinola MA, Weir EG, Ali SZ. CD56 expression of neuroendocrine neoplasms on immunophenotyping by flow cytometry: a novel diagnostic approach to fine-needle aspiration biopsy. Cancer 2003; 99: 240-246
    CrossrefPubMedGoogle Scholar
  • 8 Kanehira K, Khoury T. Neuroendocrine markers expression in pancreatic serous cystadenoma. Appl Immunohistochem Mol Morphol 2011; 19: 141-146
    PubMedGoogle Scholar
  • 9 Elias S, Delestre C, Courel M, Anouar Y, Montero-Hadjadje M. Chromogranin A as a crucial factor in the sorting of peptide hormones to secretory granules. Cell Mol Neurobiol 2010; 30: 1189-1195
    CrossrefPubMedGoogle Scholar
  • 10 Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 2010; 139: 742-753
    CrossrefPubMedGoogle Scholar
  • 11 Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003; 30: 781-793
    CrossrefPubMedGoogle Scholar
  • 12 Leja J, Essaghir A, Essand M, Wester K, Oberg K, Totterman TH, Lloyd R, Vasmatzis G, Demoulin JB, Giandomenico V. Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Mod Pathol 2009; 22: 261-272
    CrossrefPubMedGoogle Scholar
  • 13 Modlin IM, Lye KD, Kidd MA. 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959
    CrossrefPubMedGoogle Scholar
  • 14 Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle FG, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9: 61-72
    CrossrefPubMedGoogle Scholar
  • 15 Pape UF, Berndt U, Muller-Nordhorn J, Bohmig M, Roll S, Koch M, Willich SN, Wiedenmann B. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008; 15: 1083-1097
    CrossrefPubMedGoogle Scholar
  • 16 Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004; 1014: 13-27
    CrossrefPubMedGoogle Scholar
  • 17 Hodul PJ, Strosberg JR, Kvols LK. Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated?. Cancer Control 2008; 15: 314-321
    PubMedGoogle Scholar
  • 18 Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology 2005; 128: 1717-1751
    CrossrefPubMedGoogle Scholar
  • 19 Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J, Kayani I, Toumpanakis C, Grillo F, Mayer A, Hochhauser D, Begent RH, Caplin ME, Meyer T. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010; 102: 1106-1112
    CrossrefPubMedGoogle Scholar
  • 20 Turaga KK, Kvols LK. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 2011; 61: 113-132
    CrossrefPubMedGoogle Scholar
  • 21 Bushnell Jr DL, O’Dorisio TM, O’Dorisio MS, Menda Y, Hicks RJ, Van CE, Baulieu JL, Borson-Chazot F, Anthony L, Benson AB, Oberg K, Grossman AB, Connolly M, Bouterfa H, Li Y, Kacena KA, LaFrance N, Pauwels SA. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010; 28: 1652-1659
    CrossrefPubMedGoogle Scholar
  • 22 Kvols LK, Martin JK, Marsh HM, Moertel CG. Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med 1985; 313: 1229-1230
    PubMedGoogle Scholar
  • 23 Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van EM, Kooij PP, Feelders RA, van Aken MO, Krenning EP. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2130
    CrossrefPubMedGoogle Scholar
  • 24 Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002; 43: 610-616
    PubMedGoogle Scholar
  • 25 Turaga KK, Kvols LK. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 2011; 61: 113-132
    CrossrefPubMedGoogle Scholar
  • 26 Ganti AK, West WW, Lackner RP, Kessinger A. Current concepts in the diagnosis and management of small-cell lung cancer. Oncology (Williston Park) 2010; 24: 1034-1039
    PubMedGoogle Scholar
  • 27 Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362: 2202-2211
    CrossrefPubMedGoogle Scholar
  • 28 Alvarez MC, Macias AA, Saurez MG, Fernandez ML, Lage DA. Bronchial carcinoid tumor treated with interferon and a new vaccine against NeuGcGM3 antigen expressed in malignant carcinoid cells. Cancer Biol Ther 2007; 6: 853-855
    CrossrefPubMedGoogle Scholar
  • 29 Neninger E, Diaz RM, de la Torre A, Rives R, Diaz A, Saurez G, Gabri MR, Alonso DF, Wilkinson B, Alfonso AM, Combet T, Perez R, Vazquez AM. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol Ther 2007; 6: 145-150
    CrossrefPubMedGoogle Scholar
  • 30 Papewalis C, Wuttke M, Jacobs B, Domberg J, Willenberg H, Baehring T, Cupisti K, Raffel A, Chao L, Fenk R, Seissler J, Scherbaum WA, Schott M. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma. Horm Metab Res 2008; 40: 108-116
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Russell HV, Strother D, Mei Z, Rill D, Popek E, Biagi E, Yvon E, Brenner M, Rousseau R. Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother 2007; 30: 227-233
    CrossrefPubMedGoogle Scholar
  • 32 Haupt K, Siegel F, Lu M, Yang D, Hilken G, Mann K, Roggendorf M, Saller B. Induction of a cellular and humoral immune response against preprocalcitonin by genetic i: a potential new treatment for medullary thyroid carcinoma. Endocrinology 2001; 142: 1017-1023
    CrossrefPubMedGoogle Scholar
  • 33 Ray S, Chhabra A, Mehrotra S, Chakraborty NG, Ribas A, Economou J, Mukherji B. Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma. Clin Dermatol 2009; 27: 603-613
    CrossrefPubMedGoogle Scholar
  • 34 Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 715-727
    CrossrefPubMedGoogle Scholar
  • 35 Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-360
    CrossrefPubMedGoogle Scholar
  • 36 Wilczynski JR, Duechler M. How do tumors actively escape from host immunosurveillance?. Arch Immunol Ther Exp (Warsz) 2010; 58: 435-448
    CrossrefPubMedGoogle Scholar
  • 37 Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-1111
    CrossrefPubMedGoogle Scholar
  • 38 Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 2000; 192: 755-760
    CrossrefPubMedGoogle Scholar
  • 39 Wilczynski JR, Duechler M. How do tumors actively escape from host immunosurveillance?. Arch Immunol Ther Exp (Warsz) 2010; 58: 435-448
    CrossrefPubMedGoogle Scholar
  • 40 Lathers DM, Achille NJ, Young MR. Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. Hum Immunol 2003; 64: 1160-1166
    CrossrefPubMedGoogle Scholar
  • 41 Lauerova L, Dusek L, Simickova M, Kocak I, Vagundova M, Zaloudik J, Kovarik J. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 2002; 49: 159-166
    PubMedGoogle Scholar
  • 42 Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006; 66: 11238-11246
    CrossrefPubMedGoogle Scholar
  • 43 Wilczynski JR, Kalinka J, Radwan M. The role of T-regulatory cells in pregnancy and cancer. Front Biosci 2008; 13: 2275-2289
    CrossrefPubMedGoogle Scholar
  • 44 Aktas S. Future aspects of immunotherapy and gene therapy in neuroblastoma. J BUON 2009; 14 (Suppl 1) S175-S179
    PubMedGoogle Scholar
  • 45 Miles SA, Sandler AD. CpG oligonucleotides for immunotherapeutic treatment of neuroblastoma. Adv Drug Deliv Rev 2009; 61: 275-282
    CrossrefPubMedGoogle Scholar
  • 46 Caruso DA, Orme LM, Amor GM, Neale AM, Radcliff FJ, Downie P, Tang ML, Ashley DM. Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma. Cancer 2005; 103: 1280-1291
    CrossrefPubMedGoogle Scholar
  • 47 Russell HV, Strother D, Mei Z, Rill D, Popek E, Biagi E, Yvon E, Brenner M, Rousseau R. A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. J Immunother 2008; 31: 812-819
    CrossrefPubMedGoogle Scholar
  • 48 Brown CE, Vishwanath RP, Aguilar B, Starr R, Najbauer J, Aboody KS, Jensen MC. Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol 2007; 179: 3332-3341
    PubMedGoogle Scholar
  • 49 Song L, Ara T, Wu HW, Woo CW, Reynolds CP, Seeger RC, DeClerck YA, Thiele CJ, Sposto R, Metelitsa LS. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. J Clin Invest 2007; 117: 2702-2712
    CrossrefPubMedGoogle Scholar
  • 50 Coughlin CM, Fleming MD, Carroll RG, Pawel BR, Hogarty MD, Shan X, Vance BA, Cohen JN, Jairaj S, Lord EM, Wexler MH, Danet-Desnoyers GA, Pinkus JL, Pinkus GS, Maris JM, Grupp SA, Vonderheide RH. Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma. J Clin Oncol 2006; 24: 5725-5734
    CrossrefPubMedGoogle Scholar
  • 51 De GA, Carlson LM, Kogner P, Levitskaya J. Soluble factors released by activated cytotoxic T lymphocytes interfere with death receptor pathways in neuroblastoma. Cancer Immunol Immunother 2008; 57: 731-743
    CrossrefPubMedGoogle Scholar
  • 52 Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008; 14: 1264-1270
    CrossrefPubMedGoogle Scholar
  • 53 Forloni M, Albini S, Limongi MZ, Cifaldi L, Boldrini R, Nicotra MR, Giannini G, Natali PG, Giacomini P, Fruci D. NF-kappaB and not MYCN, regulates MHC class I and endoplasmic reticulum aminopeptidases in human neuroblastoma cells. Cancer Res 2010; 70: 916-924
    CrossrefPubMedGoogle Scholar
  • 54 Raffaghello L, Prigione I, Bocca P, Morandi F, Camoriano M, Gambini C, Wang X, Ferrone S, Pistoia V. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene 2005; 24: 4634-4644
    CrossrefPubMedGoogle Scholar
  • 55 Ash S, Gigi V, Askenasy N, Fabian I, Stein J, Yaniv I. Graft versus neuroblastoma reaction is efficiently elicited by allogeneic bone marrow transplantation through cytolytic activity in the absence of GVHD. Cancer Immunol Immunother 2009; 58: 2073-2084
    CrossrefPubMedGoogle Scholar
  • 56 Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother 2008; 57: 987-996
    CrossrefPubMedGoogle Scholar
  • 57 Morandi F, Levreri I, Bocca P, Galleni B, Raffaghello L, Ferrone S, Prigione I, Pistoia V. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res 2007; 67: 6433-6441
    CrossrefPubMedGoogle Scholar
  • 58 Zhou Q, Yan X, Gershan J, Orentas RJ, Johnson BD. Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo. J Immunol 2008; 181: 1877-1886
    PubMedGoogle Scholar
  • 59 Ash S, Gigi V, Askenasy N, Fabian I, Stein J, Yaniv I. Graft versus neuroblastoma reaction is efficiently elicited by allogeneic bone marrow transplantation through cytolytic activity in the absence of GVHD. Cancer Immunol Immunother 2009; 58: 2073-2084
    CrossrefPubMedGoogle Scholar
  • 60 Ash S, Stein J, Askenasy N, Yaniv I. Immunomodulation with dendritic cells and donor lymphocyte infusion converge to induce graft vs neuroblastoma reactions without GVHD after allogeneic bone marrow transplantation. Br J Cancer 2010; 103: 1597-1605
    CrossrefPubMedGoogle Scholar
  • 61 Clark EM, Joshi DS, Grimm AB, Joshi AD, Wang P, Joshi SS. Ultrastructural basis of enhanced antitumor cytotoxicity of cord blood-derived CTLs: a comparative analysis with peripheral blood and bone marrow. Int J Oncol 2010; 37: 645-653
    PubMedGoogle Scholar
  • 62 Kohler ME, Hallett WH, Chen QR, Khan J, Johnson BD, Orentas RJ. Early expression of stem cell-associated genes within the CD8 compartment after treatment with a tumor vaccine. Cell Immunol 2010; 265: 65-73
    CrossrefPubMedGoogle Scholar
  • 63 Chargui J, Combaret V, Scaglione V, Iacono I, Peri V, Valteau-Couanet D, Dubrel M, Angevin E, Puisieux A, Romagne F, Bergeron C. Bromohydrin pyrophosphate-stimulated Vgamma9delta2 T cells expanded ex vivo from patients with poor-prognosis neuroblastoma lyse autologous primary tumor cells. J Immunother 2010; 33: 591-598
    CrossrefPubMedGoogle Scholar
  • 64 Schilbach K, Frommer K, Meier S, Handgretinger R, Eyrich M. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy. J Immunother 2008; 31: 896-905
    CrossrefPubMedGoogle Scholar
  • 65 Song L, Asgharzadeh S, Salo J, Engell K, Wu HW, Sposto R, Ara T, Silverman AM, DeClerck YA, Seeger RC, Metelitsa LS. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest 2009; 119: 1524-1536
    CrossrefPubMedGoogle Scholar
  • 66 Croce M, Corrias MV, Orengo AM, Brizzolara A, Carlini B, Borghi M, Rigo V, Pistoia V, Ferrini S. Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice. Int J Cancer 2010; 127: 1141-1150
    PubMedGoogle Scholar
  • 67 Jing W, Gershan JA, Johnson BD. Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory. Blood 2009; 113: 4449-4457
    CrossrefPubMedGoogle Scholar
  • 68 Balza E, Carnemolla B, Mortara L, Castellani P, Soncini D, Accolla RS, Borsi L. Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha. Int J Cancer 2010; 127: 101-110
    CrossrefPubMedGoogle Scholar
  • 69 Reid GS, Shan X, Coughlin CM, Lassoued W, Pawel BR, Wexler LH, Thiele CJ, Tsokos M, Pinkus JL, Pinkus GS, Grupp SA, Vonderheide RH. Interferon-gamma-dependent infiltration of human T cells into neuroblastoma tumors in vivo. Clin Cancer Res 2009; 15: 6602-6608
    CrossrefPubMedGoogle Scholar
  • 70 Salcedo R, Hixon JA, Stauffer JK, Jalah R, Brooks AD, Khan T, Dai RM, Scheetz L, Lincoln E, Back TC, Powell D, Hurwitz AA, Sayers TJ, Kastelein R, Pavlakis GN, Felber BK, Trinchieri G, Wigginton JM. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J Immunol 2009; 182: 4328-4338
    CrossrefPubMedGoogle Scholar
  • 71 Tagalakis AD, Grosse SM, Meng QH, Mustapa MF, Kwok A, Salehi SE, Tabor AB, Hailes HC, Hart SL. Integrin-targeted nanocomplexes for tumour specific delivery and therapy by systemic administration. Biomaterials 2011; 32: 1370-1376
    CrossrefPubMedGoogle Scholar
  • 72 Sun J, Dotti G, Huye LE, Foster AE, Savoldo B, Gramatges MM, Spencer DM, Rooney CM. T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol Ther 2010; 18: 2006-2017
    CrossrefPubMedGoogle Scholar
  • 73 Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, Foster AE. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother 2010; 33: 780-788
    CrossrefPubMedGoogle Scholar
  • 74 Gil M, Bieniasz M, Wierzbicki A, Bambach BJ, Rokita H, Kozbor D. Targeting a mimotope vaccine to activating Fcgamma receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice. J Immunol 2009; 183: 6808-6818
    CrossrefPubMedGoogle Scholar
  • 75 Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C, Pende D, Steinle A, Ferrone S, Pistoia V. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004; 6: 558-568
    CrossrefPubMedGoogle Scholar
  • 76 Johann PD, Vaegler M, Gieseke F, Mang P, Armeanu-Ebinger S, Kluba T, Handgretinger R, Muller I. Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicity. BMC Cancer 2010; 10: 501
    CrossrefPubMedGoogle Scholar
  • 77 Venstrom JM, Zheng J, Noor N, Danis KE, Yeh AW, Cheung IY, Dupont B, O’Reilly RJ, Cheung NK, Hsu KC. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res 2009; 15: 7330-7334
    CrossrefPubMedGoogle Scholar
  • 78 Xu H, Cheung IY, Guo HF, Cheung NK. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res 2009; 69: 6275-6281
    CrossrefPubMedGoogle Scholar
  • 79 Jarahian M, Watzl C, Issa Y, Altevogt P, Momburg F. Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells. Int J Cancer 2007; 120: 2625-2634
    CrossrefPubMedGoogle Scholar
  • 80 Castriconi R, Dondero A, Corrias MV, Lanino E, Pende D, Moretta L, Bottino C, Moretta A. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res 2004; 64: 9180-9184
    CrossrefPubMedGoogle Scholar
  • 81 Altvater B, Landmeier S, Pscherer S, Temme J, Schweer K, Kailayangiri S, Campana D, Juergens H, Pule M, Rossig C. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res 2009; 15: 4857-4866
    CrossrefPubMedGoogle Scholar
  • 82 Morandi F, Levreri I, Bocca P, Galleni B, Raffaghello L, Ferrone S, Prigione I, Pistoia V. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res 2007; 67: 6433-6441
    CrossrefPubMedGoogle Scholar
  • 83 Buhtoiarov IN, Sondel PM, Eickhoff JC, Rakhmilevich A. Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides. Immunology 2007; 120: 412-423
    CrossrefPubMedGoogle Scholar
  • 84 Lum HD, Buhtoiarov IN, Schmidt BE, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages. J Leukoc Biol 2006; 79: 1181-1192
    CrossrefPubMedGoogle Scholar
  • 85 Walker SR, Redlinger Jr RE, Barksdale Jr EM. Neuroblastoma-induced inhibition of dendritic cell IL-12 production via abrogation of CD40 expression. J Pediatr Surg 2005; 40: 244-249
    CrossrefPubMedGoogle Scholar
  • 86 Walker SR, Ogagan PD, DeAlmeida D, Aboka AM, Barksdale Jr EM. Neuroblastoma impairs chemokine-mediated dendritic cell migration in vitro. J Pediatr Surg 2006; 41: 260-265
    CrossrefPubMedGoogle Scholar
  • 87 Jensen M, Tawadros S, Sedlacek HH, Schultze JL, Berthold F. NK cell depletion diminish tumour-specific B cell responses. Immunol Lett 2004; 93: 205-210
    CrossrefPubMedGoogle Scholar
  • 88 Kuramochi K, Matsui R, Matsubara Y, Nakai J, Sunoki T, Arai S, Nagata S, Nagahara Y, Mizushina Y, Ikekita M, Kobayashi S. Apoptosis-inducing effect of epolactaene derivatives on BALL-1 cells. Bioorg Med Chem 2006; 14: 2151-2161
    CrossrefPubMedGoogle Scholar
  • 89 Blaheta RA, Powerski M, Hudak L, Juengel E, Jonas D, von KA, Doerr HW, Cinatl Jr J. Tumor-endothelium cross talk blocks recruitment of neutrophils to endothelial cells: a novel mechanism of endothelial cell anergy. Neoplasia 2009; 11: 1054-1063
    PubMedGoogle Scholar
  • 90 Chong S, Lee KS, Chung MJ, Han J, Kwon OJ, Kim TS. Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings. Radiographics 2006; 26: 41-57
    CrossrefPubMedGoogle Scholar
  • 91 Toh CK, Gao F, Lim WT, Leong SS, Fong KW, Yap SP, Hsu AA, Eng P, Koong HN, Thirugnanam A, Tan EH. Differences between small-cell lung cancer and non-small-cell lung cancer among tobacco smokers. Lung Cancer 2007; 56: 161-166
    CrossrefPubMedGoogle Scholar
  • 92 Aladin F, Lautscham G, Humphries E, Coulson J, Blake N. Targeting tumour cells with defects in the MHC Class I antigen processing pathway with CD8+ T cells specific for hydrophobic TAP- and Tapasin-independent peptides: the requirement for directed access into the ER. Cancer Immunol Immunother 2007; 56: 1143-1152
    CrossrefPubMedGoogle Scholar
  • 93 Schutt P, Schutt B, Switala M, Bauer S, Stamatis G, Opalka B, Eberhardt W, Schuler M, Horn PA, Rebmann V. Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients. Hum Immunol 2010; 71: 489-495
    CrossrefPubMedGoogle Scholar
  • 94 Sorrentino C, Di CE. Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med 2009; 180: 769-779
    CrossrefPubMedGoogle Scholar
  • 95 Zhan P, Wang J, Lv XJ, Wang Q, Qiu LX, Lin XQ, Yu LK, Song Y. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 2009; 4: 1094-1103
    CrossrefPubMedGoogle Scholar
  • 96 Karanikas V, Khalil S, Kerenidi T, Gourgoulianis KI, Germenis AE. Anti-survivin antibody responses in lung cancer. Cancer Lett 2009; 282: 159-166
    CrossrefPubMedGoogle Scholar
  • 97 Rotondo R, Mastracci L, Piazza T, Barisione G, Fabbi M, Cassanello M, Costa R, Morandi B, Astigiano S, Cesario A, Sormani MP, Ferlazzo G, Grossi F, Ratto GB, Ferrini S, Frumento G. Arginase 2 is expressed by human lung cancer, but it neither induces immune suppression, nor affects disease progression. Int J Cancer 2008; 123: 1108-1116
    CrossrefPubMedGoogle Scholar
  • 98 Jusufovic E, Iljazovic E, Kosnik M, Keser D, Keser D, Korosec P, Zukic E, Prnjavorac B, Sejdinovic R, Ajanovic E. Local CD4+ CD8+ and CD56+ reactions to lung cancer in regard to pathohistological type and clinical stage. Med Glas Ljek Komore Zenicko-doboj Kantona 2011; 8: 101-108
    PubMedGoogle Scholar
  • 99 Karagoz B, Bilgi O, Gumus M, Erikci AA, Sayan O, Turken O, Kandemir EG, Ozturk A, Yaylaci M. CD8+. Med Oncol 2010; 27: 29-33
    CrossrefPubMedGoogle Scholar
  • 100 Tarkan-Arguden Y, Hacihanefioglul S, Ongen G, Erk M, Cenani A. 3p abnormalities in peripheral lymphocytes in small cell lung cancer. Tumori 2009; 95: 535-537
    PubMedGoogle Scholar
  • 101 Ciszak L, Kosmaczewska A, Werynska B, Szteblich A, Jankowska R, Frydecka I. Impaired zeta chain expression and IFN-gamma production in peripheral blood T and NK cells of patients with advanced lung cancer. Oncol Rep 2009; 21: 173-184
    PubMedGoogle Scholar
  • 102 Koyama K, Kagamu H, Miura S, Hiura T, Miyabayashi T, Itoh R, Kuriyama H, Tanaka H, Tanaka J, Yoshizawa H, Nakata K, Gejyo F. Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res 2008; 14: 6770-6779
    CrossrefPubMedGoogle Scholar
  • 103 Al OS, Middleton D, Marshall E, Porter D, Xinarianos G, Raji O, Field JK, Christmas SE. Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. Hum Immunol 2010; 71: 976-981
    CrossrefPubMedGoogle Scholar
  • 104 Sodeur S, Ullrich S, Gustke H, Zangemeister-Wittke U, Schumacher U. Increased numbers of spontaneous SCLC metastasis in absence of NK cells after subcutaneous inoculation of different SCLC cell lines into pfp/rag2 double knock out mice. Cancer Lett 2009; 282: 146-151
    CrossrefPubMedGoogle Scholar
  • 105 Izycka A, Jablonska E, Izycki T, Chyczewska E. Expression of L-selectin on the surface of neutrophils stimulated by TNF-alpha and level of sL-selectin in serum of patients with lung cancer. Pol Merkur Lekarski 2005; 18: 62-65
    PubMedGoogle Scholar
  • 106 Li M, Zhang H, Tang W. Detection of interleukin-10 in alveolar macrophage and peripheral blood monocyte from lung cancer patients and its clinical significance. Zhongguo Fei Ai Za Zhi 2004; 7: 158-160
    PubMedGoogle Scholar
  • 107 Vikman S, Sommaggio R, De La Torre M, Oberg K, Essand M, Giandomenico V, Loskog A, Totterman TH. Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue. Acta Oncol 2009; 48: 391-400
    CrossrefPubMedGoogle Scholar
  • 108 Katz SC, Donkor C, Glasgow K, Pillarisetty VG, Gonen M, Espat NJ, Klimstra DS, D’Angelica MI, Allen PJ, Jarnagin W, Dematteo RP, Brennan MF, Tang LH. T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases. HPB (Oxford) 2010; 12: 674-683
    CrossrefPubMedGoogle Scholar
  • 109 Lyman MA, Nugent CT, Marquardt KL, Biggs JA, Pamer EG, Sherman LA. The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice. J Immunol 2005; 174: 2563-2572
    PubMedGoogle Scholar
  • 110 Wong SB, Bos R, Sherman LA. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol 2008; 180: 3122-3131
    PubMedGoogle Scholar
  • 111 Zwicker K, Chatten C, Gratton K, Demetrick D, Serra P, Shameli A, Santamaria P, Bathe OF. Spontaneous autoimmunity sufficiently potent to induce diabetes mellitus is insufficient to protect against insulinoma. J Immunol 2009; 183: 1705-1714
    CrossrefPubMedGoogle Scholar
  • 112 Muller-Hermelink N, Braumuller H, Pichler B, Wieder T, Mailhammer R, Schaak K, Ghoreschi K, Yazdi A, Haubner R, Sander CA, Mocikat R, Schwaiger M, Forster I, Huss R, Weber WA, Kneilling M, Rocken M. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 2008; 13: 507-518
    CrossrefPubMedGoogle Scholar
  • 113 Wang M, Zhao XR, Wang P, Li L, Dai Y, Huang H, Lei P, Zhu HF, Shen GX. Glucose regulated proteins 78 protects insulinoma cells (NIT-1) from death induced by streptozotocin, cytokines or cytotoxic T lymphocytes. Int J Biochem Cell Biol 2007; 39: 2076-2082
    CrossrefPubMedGoogle Scholar
  • 114 Mertz KD, Junt T, Schmid M, Pfaltz M, Kempf W. Inflammatory monocytes are a reservoir for Merkel cell polyomavirus. J Invest Dermatol 2010; 130: 1146-1151
    CrossrefPubMedGoogle Scholar
  • 115 Beer TW, Ng LB, Murray K. Mast cells have prognostic value in Merkel cell carcinoma. Am J Dermatopathol 2008; 30: 27-30
    CrossrefPubMedGoogle Scholar
  • 116 Ng L, Beer TW, Murray K. Vascular density has prognostic value in Merkel cell carcinoma. Am J Dermatopathol 2008; 30: 442-445
    CrossrefPubMedGoogle Scholar
  • 117 Lu K, Lamagna C, Bergers G. Chapter 3 Bone marrow-derived vascular progenitors and proangiogenic monocytes in tumors. Methods Enzymol 2008; 445: 53-82
    CrossrefPubMedGoogle Scholar
  • 118 Zumsteg A, Baeriswyl V, Imaizumi N, Schwendener R, Ruegg C, Christofori G. Myeloid cells contribute to tumor lymphangiogenesis. PLoS One 2009; 4: e7067
    CrossrefPubMedGoogle Scholar
  • 119 Kang JM, Lee WJ, Kim WB, Kim TY, Koh JM, Hong SJ, Huh J, Ro JY, Chi HS, Kim MS. Systemic inflammatory syndrome and hepatic inflammatory cell infiltration caused by an interleukin-6 producing pheochromocytoma. Endocr J 2005; 52: 193-198
    CrossrefPubMedGoogle Scholar
  • 120 Sevastos N, Theodossiades G, Malaktari S, Archimandritis AJ. Persistent neutrophilia as a preceding symptom of pheochromocytoma. J Clin Endocrinol Metab 2005; 90: 2472-2473
    PubMedGoogle Scholar
  • 121 Zelinka T, Petrak O, Strauch B, Holaj R, Kvasnicka J, Mazoch J, Pacak K, Widimsky Jr J. Elevated inflammation markers in pheochromocytoma compared to other forms of hypertension. Neuroimmunomodulat 2007; 14: 57-64
    PubMedGoogle Scholar